Impact Investment Summit Asia Pacific’s Post

Join us in this in-depth Executive interview with Hashan De Silva, CFA, Founder of KP Rx, as he shares the journey behind launching a specialist healthcare VC firm. Learn how KP Rx is transforming biotech and medical device investments in Australia and New Zealand by capitalising on key market advantages. Hashan explains the firm’s unique approach, valuation arbitrage, and insights into healthcare investment strategies that have yielded significant success. Steve Torso

What trends will shape the future of health and life sciences over the next decade? How should we invest in healthcare and track impact? What does it take to validate effective research and innovations in medicine? We’re diving into these questions during on online roundtable with Anya Schiess, Managing Partner at J.P. Morgan Asset Management, on 21 November 15:00-16:00 GMT, as she shares insights on investing in the future of health. 💡 Join the conversation and get ahead of the trends shaping healthcare investment. It's your last chance to register now! #Healthcare #LifeSciences #Investing #PensionforPurpose https://ow.ly/s0IT50U8WyX

🔍 Use Case Spotlight: Transforming Access to Healthcare & Education Investments A UK-based investment firm specializing in healthcare and education has turned to Scintilla’s fractionalized bond issuance service to bring vital projects to a broader audience. Through our technology, they’re able to: ➡️ Broaden Access: Lower entry barriers allow a more diverse range of investors to participate. By democratizing access, high-value healthcare and education projects are no longer reserved for large institutional players—empowering retail investors to make an impact. ➡️ Boost Liquidity: Fractional ownership supports active secondary markets, enhancing liquidity. Investors can buy and sell portions of assets more freely, enabling greater flexibility and more efficient allocation of capital. ➡️ Reduce Costs: Streamlined, digital-first issuance minimizes costs and accelerates processes. By reducing intermediaries, the firm can focus on delivering value to stakeholders while maintaining efficiency. This partnership underscores Scintilla’s mission to democratize real-world asset investments, ensuring that high-impact sectors like healthcare and education are accessible to all. 💡 Learn how Scintilla’s solutions can transform your investment opportunities. Visit scintillanetwork.com or connect with us today. #ScintillaNetwork #FractionalizedBonds #DigitalAssets #HealthcareInvestment #EducationFinance

UK Investment Summit 2024. A number of really large global companies invited and an announcement that £64bn pledged in investment. Great news! David Ricks, CEO of Eli Lilly, shared an interesting perspective on investing in the UK with Sean Farrington from BBC #WakeUpToMoney (Oct 15, 2024). In comparison to the US and Europe, the UK is a small market that is disconnected from the bigger market on it's door step. If the country wants investment from the likes of Eli Lilly, or better still, grow our own large company, the UK needs to encourage innovation and utilise real world studies of effects - in other words, be an incubator for ideas and have a willingness to test new approaches. This doesn't just relate to drugs, it stands for any industry. Time to get in front of the wave and help to shape the future rather than locked in to the pitting cycle of the undertow. David Crack FICA Patrick Smith Ayaan Mohamed Ali Michael Jakubiak Anthony H. #Innovation #RealWorldImpact #Investment #PilotProjects

Morgan Stanley article: 3 Healthcare Investing Trends to Watch   3 key take aways: Interest rate reductions and a lower cost of capital may help fuel more healthcare M&A deals and IPOs. Artificial intelligence is helping maximize productivity and reduce administrative costs, leaving investors assessing the possible return on investment.  Companies shared innovations in digital health and biotechnology, as well as positive utilization trends.   #healthcare #investing #trendstowatch   https://lnkd.in/dvxBbq4K

Over the last few weeks, I have discussed how I expect a big year in Australia's Life Science companies in 2025. In this Executive Interview, Hashan De Silva, CFA, Founder and Managing Partner of KPRX, a specialist healthcare VC firm, shares his insights into the unique advantages of the Australian and New Zealand healthcare sectors. https://lnkd.in/eR48W-4E

💡 #InvestorCall: Building the next big thing in health tech? Innovestor Life Science, a 90m€ Finland-based fund, is actively seeking new investment opportunities in the Nordics and Baltics! If you're developing science-based or evidence-backed digital health and therapeutics products, this #InvestorCall could be the perfect fit for you. Details: - Investment Stage: Pre-Seed to Series A - Investment Range: 500k€-3m€ - Focus: All therapeutic areas - Region: Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania To learn more and apply on R2GConnect.com: https://lnkd.in/dAjbQ2Kc #Investors: Visit R2GConnect.com to set up your own 'Investor Call' for #free. For a demo, contact Sorin STIRCU, Partnerships Manager: https://bit.ly/3TGL2kF #investorcall #investorservice #funding #globalhealth #startupfunding

Despite uncertainty in global M&A, interest in healthcare and life sciences (HLS) continues to weather unfavourable headwinds showing a surge in HLS megadeals with biotech and healthcare startups raising upwards of $100million. In our latest report, we surveyed 700 European investors and corporates to take the investment pulse. Download your copy and explore the key trends shaping the sector: https://lnkd.in/eSbjrNZb #healthcare #lifesciences #investments

💡 Investor Opportunity: Developing the next breakthrough in health tech? Innovestor Life Science, a Finland-based fund with €90M under management, is currently looking for investment opportunities across the Nordics and Baltics! If you're developing science-based or evidence-backed digital health and therapeutics products, this #InvestorCall could be the perfect fit for you. Details: - Investment Stage: Pre-Seed to Series A - Investment Range: 500k€-3m€ - Focus: All therapeutic areas - Region: Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania To learn more and apply on R2GConnect: https://lnkd.in/dAjbQ2Kc #Investors: Visit R2GConnect.com to set up your own 'Investor Call' for #free. For a demo, contact Sorin STIRCU, Partnerships Manager: https://bit.ly/3TGL2kF   #StartupFunding #VentureCapital #InvestorCall #HealthTechInvesting #EarlyStageInvesting #InvestmentOpportunities #DealFlow

We’re kicking off our thematic series on healthcare/biotech trusts with an interview with Dr. Andreas Wicki, CEO of HBM Healthcare Investments AG (SIX: HBMN), who shares his expert insights on the current market landscape. With biotech valuations at historic lows, breakthrough innovations in the pipeline, and a looming patent cliff for big pharma, could this be a turning point for the sector? #healthcare #biotech #investment